Search results
FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia
Pharmaceutical Technology via Yahoo Finance· 11 hours agoThe US Food and Drug Administration (FDA) has approved Amgen’s BLINCYTO (blinatumomab) for...
The Taunk family's strong bond and brotherly love is helping them through childhood leukemia battle
CBS News· 4 hours agoA child's cancer diagnosis affects the entire family and those effects can be immense and in various...
...PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE...
Morningstar· 3 days agoBLINCYTO has helped thousands of patients with B-ALL over the last 10 years.
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
Zacks· 15 hours agoALL is a fast-growing type of blood cancer that develops in the bone marrow. Consolidation treatment is given to cancer patients after their cancer has disappeared following...
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto
Morningstar· 3 days agoThe biotechnology company on Friday said the approval is aimed at adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-< ...
Rovin Capital UT ADV Acquires 274 Shares of Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 6 hours agoRovin Capital UT ADV lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 20.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange ...
Incyte (NASDAQ:INCY) Sees Strong Trading Volume
ETF DAILY NEWS· 8 hours agoIncyte Co. (NASDAQ:INCY – Get Free Report) shares saw an uptick in trading volume on Monday . Jefferies Financial Group began coverage on shares of Incyte in a report on Friday, February 23rd ...
Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Up 191.7% in May
ETF DAILY NEWS· 4 days agoDominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 3,500 ...
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of “Moderate Buy” by Analysts
ETF DAILY NEWS· 5 days agoKura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports ...
Secret Pentagon Anti-Vax Campaign; FDA's Tylenol Warning; E. Coli at the Olympics
MedPage Today· 15 hours agoThe U.S. military waged a secret campaign in the Philippines during the pandemic to cast doubt on...
